stockportfolio.pro
Anbio Biotechnology (NNNN)
Healthcare · Medical Instruments & Supplies · NasdaqGM
Anbio Biotechnology revenue & earnings — last 4 fiscal years
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $23.54M | $6.71M | $8.19M | $8.65M |
| Gross profit | $12.56M | $3.36M | $5.89M | $7.54M |
| Net income | $10.01M | $2.25M | $2.37M | $6.40M |
| Net margin | 42.5% | 33.6% | 29.0% | 74.1% |
Source: Anbio Biotechnology SEC filings (10-K).
Explore 4 years of Anbio Biotechnology financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track NNNN in your portfolio →
Anbio Biotechnology financial history by metric
About Anbio Biotechnology
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits. It serves over-the-counter, point-of-care testing, and laboratory markets. Anbio Biotechnology was incorporated in 2021 and is based in Frankfurt am Main, Germany.
Anbio Biotechnology — frequently asked questions
What is Anbio Biotechnology's revenue?
Anbio Biotechnology (NNNN) reported revenue of $8.65M for fiscal year 2025, up 5.6% from the prior year, according to its SEC filings.
Is Anbio Biotechnology profitable?
Yes. NNNN earned net income of $6.40M in fiscal 2025, a net margin of 74.1%.
What is NNNN's P/E ratio?
Anbio Biotechnology trades at a price-to-earnings ratio of about 107.4 based on the latest data in our nightly-refreshed cache.
How fast is Anbio Biotechnology growing?
NNNN's revenue grew at roughly -28.4% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Anbio Biotechnology have?
As of fiscal year 2025, NNNN carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Anbio Biotechnology's gross margin?
NNNN's gross margin was 87.2% in fiscal 2025 — gross profit of $7.54M on revenue of $8.65M.
What is Anbio Biotechnology's market cap?
Anbio Biotechnology (NNNN) has a market capitalization of about $707.09M, based on the latest data in our nightly-refreshed cache.
When does Anbio Biotechnology's fiscal year end?
NNNN's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Anbio Biotechnology's official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.